Pfizer (PFIZER.NS) Stock Price

Pfizer Price

NSE·CLOSED
4,731.40INR+141.30 (+3.03 %)
Market closed

Revenue has compounded at 6.7% per year over the past 20 years to 22.81 B INR. Earnings per share have grown at 10.5% per year over the last 20 years. Pfizer's net margin stands at 33.6%, up from 22.2% several years earlier. Pfizer currently offers a dividend yield of about 2.75%. The payout ratio is around 77% of earnings. The dividend has grown at 13.7% per year over the past 20 years. Analysts set a median price target of 6,222.00 INR, implying 31.5% above the current price. Of 8 analysts, 5 rate the stock a buy — an overall Buy consensus. The stock trades about 7% above its 52-week low.

Pfizer stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Pfizer over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pfizer stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pfizer's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Pfizer Stock Price History
DatePfizer Price
7/10/20264,731.40 INR
7/9/20264,590.10 INR
7/8/20264,532.10 INR
7/7/20264,538.70 INR
7/6/20264,577.70 INR
7/3/20264,567.20 INR
7/2/20264,439.40 INR
7/1/20264,473.60 INR
6/30/20264,439.40 INR
6/29/20264,404.90 INR
6/25/20264,460.70 INR
6/24/20264,507.20 INR
6/23/20264,497.00 INR
6/22/20264,463.30 INR
6/19/20264,533.70 INR
6/18/20264,539.30 INR
6/17/20264,493.50 INR
6/16/20264,503.10 INR
6/15/20264,518.00 INR
6/12/20264,509.20 INR
6/11/20264,499.10 INR
6/10/20264,547.50 INR
6/9/20264,592.50 INR
6/8/20264,527.90 INR
6/5/20264,452.00 INR
6/4/20264,471.80 INR
6/3/20264,465.50 INR
6/2/20264,514.50 INR
6/1/20264,545.20 INR
5/29/20264,643.90 INR
5/27/20264,687.90 INR
5/26/20264,662.20 INR
5/25/20264,692.20 INR
5/22/20264,714.30 INR
5/21/20264,705.40 INR
5/20/20264,678.00 INR
5/19/20264,785.40 INR
5/18/20264,859.30 INR
5/15/20264,954.70 INR
5/14/20264,681.10 INR
5/13/20264,613.50 INR
5/12/20264,725.90 INR
5/11/20264,875.40 INR
5/8/20264,818.80 INR
5/7/20264,750.60 INR
5/6/20264,783.20 INR
5/5/20264,698.00 INR
5/4/20264,679.00 INR
4/30/20264,710.60 INR
4/29/20264,763.00 INR
4/28/20264,820.10 INR
4/27/20264,791.40 INR
4/24/20264,733.20 INR
4/23/20264,783.20 INR
4/22/20264,764.10 INR
4/21/20264,816.50 INR
4/20/20264,894.70 INR
4/17/20264,960.70 INR
4/16/20264,859.20 INR
4/15/20264,895.40 INR
4/13/20264,851.80 INR
4/10/20264,868.60 INR
4/9/20264,749.10 INR
4/8/20264,835.70 INR
4/7/20264,779.20 INR
4/6/20264,839.90 INR
4/2/20264,887.10 INR
4/1/20264,820.00 INR
3/30/20264,730.00 INR
3/27/20264,700.00 INR
3/25/20264,706.00 INR
3/24/20264,674.50 INR
3/23/20264,524.50 INR
3/20/20264,768.00 INR
3/19/20264,720.00 INR
3/18/20264,810.00 INR
3/17/20264,724.00 INR
3/16/20264,700.00 INR
3/13/20264,623.00 INR
3/12/20264,686.00 INR
3/11/20264,700.00 INR
3/10/20264,797.00 INR
3/9/20264,788.00 INR
3/6/20264,849.50 INR
3/5/20264,824.00 INR
2/27/20265,055.00 INR
2/26/20265,085.20 INR
2/25/20265,147.60 INR
2/24/20265,098.00 INR
2/23/20265,066.60 INR
2/20/20264,950.00 INR
2/19/20264,996.00 INR
2/18/20265,100.00 INR
2/17/20265,052.80 INR
2/16/20265,020.00 INR
2/13/20265,037.50 INR
2/12/20265,105.00 INR
2/11/20265,190.00 INR
2/10/20264,960.80 INR
2/9/20264,764.10 INR
2/6/20264,590.30 INR
2/5/20264,700.00 INR
2/4/20264,745.10 INR
2/3/20264,710.10 INR
2/2/20264,589.90 INR
1/30/20264,549.90 INR
1/29/20264,599.20 INR
1/28/20264,745.00 INR
1/27/20264,607.80 INR
1/23/20264,580.00 INR
1/22/20264,738.00 INR
1/21/20264,610.30 INR
1/20/20264,650.00 INR
1/19/20264,671.00 INR
1/14/20264,819.60 INR
1/13/20264,867.00 INR
1/12/20264,823.80 INR
1/9/20264,871.80 INR
1/8/20264,806.00 INR
1/7/20264,915.60 INR
1/6/20264,907.90 INR
1/5/20264,870.40 INR
1/2/20264,887.20 INR
1/1/20264,925.00 INR
12/31/20254,969.00 INR
12/30/20254,915.00 INR
12/29/20254,959.20 INR
12/26/20255,052.30 INR
12/24/20255,045.00 INR
12/23/20255,072.00 INR
12/22/20255,129.90 INR
12/19/20255,090.00 INR
12/18/20255,100.00 INR
12/17/20255,058.50 INR
12/16/20255,021.20 INR
12/15/20255,032.00 INR
12/12/20255,034.00 INR
12/11/20255,016.00 INR
12/10/20255,017.00 INR
12/9/20254,980.00 INR
12/8/20254,988.00 INR
12/5/20254,995.00 INR
12/4/20255,005.00 INR
12/3/20254,972.50 INR
12/2/20254,974.00 INR
12/1/20254,955.50 INR
11/28/20254,975.00 INR
11/27/20254,995.00 INR
11/26/20254,985.00 INR
11/25/20254,995.00 INR
11/24/20254,968.50 INR
11/21/20255,000.50 INR
11/20/20255,005.50 INR
11/19/20255,002.00 INR
11/18/20255,010.00 INR
11/17/20255,048.00 INR
11/14/20255,074.00 INR
11/13/20255,043.50 INR
11/12/20255,015.50 INR
11/11/20254,992.50 INR
11/10/20255,111.50 INR
11/7/20255,079.00 INR
11/6/20255,069.00 INR
11/4/20255,115.00 INR
11/3/20255,181.50 INR
10/31/20255,209.00 INR
10/30/20255,295.00 INR
10/29/20255,270.00 INR
10/28/20255,284.00 INR
10/27/20255,309.00 INR
10/24/20255,326.00 INR
10/23/20255,297.50 INR
10/21/20255,310.00 INR
10/20/20255,329.50 INR
10/17/20255,331.50 INR
10/16/20255,305.00 INR
10/15/20255,320.50 INR
10/14/20255,375.00 INR
10/13/20255,529.50 INR
10/10/20255,313.50 INR
10/9/20255,252.00 INR
10/8/20255,169.00 INR
10/7/20255,220.50 INR
10/6/20255,224.50 INR
10/3/20255,220.50 INR
10/1/20255,151.00 INR
9/30/20255,036.00 INR
9/29/20254,905.50 INR
9/26/20254,931.00 INR
9/25/20254,970.00 INR
9/24/20255,005.00 INR
9/23/20255,026.00 INR
9/22/20255,062.00 INR
9/19/20255,119.00 INR
9/18/20255,179.00 INR
9/17/20255,195.00 INR
9/16/20255,135.50 INR
9/15/20255,174.50 INR
9/12/20255,227.00 INR
9/11/20255,167.00 INR
9/10/20255,142.00 INR
9/9/20255,137.00 INR
9/8/20255,143.00 INR
9/5/20255,124.00 INR
9/4/20255,155.00 INR
9/3/20255,174.00 INR
9/2/20255,107.50 INR
9/1/20255,135.00 INR
8/29/20255,151.00 INR
8/28/20255,168.00 INR
8/26/20255,249.00 INR
8/25/20255,466.50 INR
8/22/20255,641.50 INR
8/21/20255,688.50 INR
8/20/20255,651.50 INR
8/19/20255,650.00 INR
8/18/20255,766.50 INR
8/14/20255,329.50 INR
8/13/20255,115.00 INR
8/12/20255,100.00 INR
8/11/20255,060.50 INR
8/8/20254,995.00 INR
8/7/20255,012.50 INR
8/6/20255,058.00 INR
8/5/20255,092.00 INR
8/4/20255,009.00 INR
8/1/20255,054.50 INR
7/31/20255,194.50 INR
7/30/20255,260.50 INR
7/29/20255,277.00 INR
7/28/20255,300.50 INR
7/25/20255,357.50 INR
7/24/20255,254.00 INR
7/23/20255,291.00 INR
7/22/20255,287.00 INR
7/21/20255,334.50 INR
7/18/20255,319.50 INR
7/17/20255,362.00 INR
7/16/20255,345.00 INR
7/15/20255,431.00 INR
7/14/20255,415.00 INR
Access this data via the Eulerpool API
Get Free API Key

Pfizer Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
22.39 B INR
6.10 B INR
4.98 B INR
Jan 1, 2022
26.11 B INR
7.30 B INR
6.13 B INR
Jan 1, 2023
24.25 B INR
7.12 B INR
6.24 B INR
Jan 1, 2024
21.93 B INR
5.83 B INR
5.51 B INR
Jan 1, 2025
22.81 B INR
6.94 B INR
7.68 B INR
Jan 1, 2026 (e)
25.64 B INR
9.21 B INR
7.71 B INR
Jan 1, 2027 (e)
27.89 B INR
10.30 B INR
8.48 B INR
Jan 1, 2028 (e)
30.29 B INR
10.78 B INR
9.33 B INR

Pfizer Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 5:39 AM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
10.4911.1218.5320.9420.4219.8020.8221.5222.3926.1124.2521.9322.8125.6427.8930.29
-4.076.0166.6912.98-2.48-3.025.123.374.0316.64-7.13-9.554.0212.418.768.59
36.4961.6056.1955.2853.9158.9060.7760.4261.6461.3761.7461.6162.3462.3462.3462.34
3.836.8510.4111.5811.0111.6612.6513.0013.8016.0214.9713.5114.2215.9917.3918.88
-1.482.210.703.053.373.604.295.094.986.136.245.517.687.718.489.33
-180.01-249.56-68.40336.9610.436.9219.1618.64-2.2623.091.86-11.6439.230.3810.0610.04
380.00–12.5015.005.00–22.50330.005.00–5.00–130.0041.4641.4649.12
2,940.00––20.00-66.67––1,366.67-98.48––––-68.11–18.48
45.7530.0046.0046.0046.0046.0046.0046.0045.7545.7545.7545.7545.7545.7545.7545.75
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Pfizer generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pfizer retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pfizer's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Pfizer has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pfizer's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Pfizer stock margins

The Pfizer margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pfizer. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pfizer.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
61.64 %
27.27 %
22.23 %
Jan 1, 2022
61.37 %
27.96 %
23.46 %
Jan 1, 2023
61.74 %
29.38 %
25.73 %
Jan 1, 2024
61.61 %
26.60 %
25.14 %
Jan 1, 2025
62.34 %
30.41 %
33.65 %
Jan 1, 2026 (e)
62.34 %
35.91 %
30.05 %
Jan 1, 2027 (e)
62.34 %
36.92 %
30.41 %
Jan 1, 2028 (e)
62.34 %
35.59 %
30.81 %

Pfizer Stock Revenue, EBIT, Earnings per Share

The Pfizer earnings per share therefore indicates how much revenue Pfizer has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
489.30 INR
133.44 INR
108.77 INR
Jan 1, 2022
570.70 INR
159.56 INR
133.89 INR
Jan 1, 2023
530.00 INR
155.73 INR
136.38 INR
Jan 1, 2024
479.38 INR
127.52 INR
120.51 INR
Jan 1, 2025
498.68 INR
151.67 INR
167.79 INR
Jan 1, 2026 (e)
560.53 INR
201.30 INR
168.44 INR
Jan 1, 2027 (e)
609.65 INR
225.10 INR
185.39 INR
Jan 1, 2028 (e)
662.04 INR
235.62 INR
203.97 INR

Pfizer business model & stock analysis

Pfizer Ltd is a global biopharmaceutical company based in New York City, USA. The company was founded in 1849 by cousins Charles Pfizer and Charles Erhart, and has achieved numerous milestones in the pharmaceutical industry during its 170-year history. Pfizer's business model is based on the research, development, production, and distribution of innovative drugs and vaccines for a variety of diseases. With a diverse portfolio of products, the company's range extends from drugs for cancer, inflammation, and immunology to neurological and cardiology conditions. Pfizer is a global leader in the development of cancer drugs and has achieved groundbreaking research successes in recent years. Key divisions of the company include oncology, pain management, cardiology, and neurology. Pfizer places great emphasis on putting patients and their needs at the center and works closely with medical professionals, patient groups, and authorities to ensure the best possible patient care. Pfizer is a leading provider of vaccines and has achieved significant breakthroughs in the development of COVID-19 vaccines in recent years. In December 2020, the company was one of the first worldwide to bring a vaccine against the coronavirus to market, making a significant contribution to the fight against the pandemic. In addition to drug research and development, Pfizer is also heavily involved in corporate social responsibility. The company is committed to sustainable development and continuously works to reduce its carbon footprint. The Pfizer Foundation also supports numerous nonprofit organizations and projects in the areas of health, education, and environmental protection. Among Pfizer's most well-known products are medications such as Viagra, Lipitor, and Lyrica, as well as the COVID-19 vaccine Comirnaty. Pfizer has offices in over 150 countries and employs over 90,000 people worldwide. Like any global company, Pfizer faces challenges. The company is often criticized for high drug prices and the availability of medications in developing countries. However, Pfizer actively advocates for access to affordable healthcare and delivers drugs and vaccines to all regions of the world. Overall, Pfizer is a company of great importance in the global healthcare industry. Through its research and development of innovative drugs and vaccines, the company contributes to improving the quality of life for millions of people worldwide.

Pfizer SWOT Analysis

Strengths

Pfizer Ltd, a leading pharmaceutical company, has several strengths that contribute to its success in the market. These include:

  • Strong brand reputation: Pfizer is globally recognized for producing high-quality and effective medications.
  • Diverse product portfolio: The company offers a wide range of pharmaceutical products, catering to various therapeutic areas.
  • Extensive research and development capabilities: Pfizer invests heavily in R&D, enabling it to innovate and develop new drugs.
  • Established distribution network: The company has a strong distribution network, ensuring efficient supply chain management.
  • Strong financial position: Pfizer boasts a solid financial position, allowing it to invest in growth opportunities.
  • Global presence: The company operates in numerous countries, providing it with a significant international market share.

Weaknesses

Despite its strengths, Pfizer Ltd faces certain weaknesses that it needs to address to maintain its competitive edge:

  • Dependency on key products: The company relies heavily on a few blockbuster drugs, making it vulnerable to patent expirations.
  • Regulatory challenges: The pharmaceutical industry is subject to stringent regulations, which can impact Pfizer's operations.
  • Slow product development cycle: Pfizer's complex R&D process can lead to delays in bringing new products to market.
  • Competitive pressure: The company faces intense competition from other pharmaceutical giants, which can affect market share.

Opportunities

Pfizer Ltd has several opportunities to explore and capitalize on for future growth and expansion:

  • Increasing demand for personalized medicine: Pfizer can develop targeted therapies to cater to the growing trend of personalized healthcare.
  • Expanding into emerging markets: The company can tap into high-growth markets in Asia, Latin America, and Africa to increase market reach.
  • Strategic partnerships and acquisitions: Pfizer can pursue collaborations and acquisitions to enhance its product portfolio and research capabilities.
  • Investment in digital healthcare solutions: The advancement of digital technologies presents opportunities for Pfizer to develop connected healthcare offerings.

Threats

Pfizer Ltd faces certain threats that could potentially hinder its growth and profitability:

  • Patent expirations: The loss of exclusivity for key drugs can result in revenue decline due to generic competition.
  • Price pressures and healthcare reforms: Increasing pricing pressures from governments and healthcare reforms can impact Pfizer's pricing strategies.
  • Adverse drug events: Any safety issues or product recalls can harm Pfizer's reputation and lead to legal complexities.
  • Pandemics and global health crises: Outbreaks of infectious diseases can disrupt supply chains and impact Pfizer's operations.

Pfizer Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Pfizer historical P/E ratio, EBIT multiple, and P/S ratio

Pfizer annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Pfizer shares outstanding

The number of shares of Pfizer was 45.75 M in 2025. This indicates how many shares Pfizer is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
45.75 M Stocks
Jan 1, 2022
45.75 M Stocks
Jan 1, 2023
45.75 M Stocks
Jan 1, 2024
45.75 M Stocks
Jan 1, 2025
45.75 M Stocks
Jan 1, 2026 (e)
45.75 M Stocks
Jan 1, 2027 (e)
45.75 M Stocks
Jan 1, 2028 (e)
45.75 M Stocks

Pfizer stock splits

In Pfizer's history, there have been no stock splits.

Pfizer Dividend History

31 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
2025130.00INR↑ 271.4%1×
Jul 9, 2025130.00INR↑ 271.4%1/1
202435.00INR↑ 600.0%1×
20235.00INR↓ 92.3%1×
202265.00INR↑ 1,200.0%2×
20215.00INR↓ 98.5%1×
2020330.00INR↑ 1,366.7%2×
201922.50INR↑ 12.5%1×
201820.00INR↑ 300.0%1×
20175.00INR↓ 66.7%1×
201615.00INR↑ 20.0%1×

Pfizer dividend history and estimates

In 2025, Pfizer paid a dividend amounting to 130.00 INR. Dividend means that Pfizer distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021
5.00 INR
0.00 INR
320.00 INR
Jan 1, 2022 (e)
65.00 INR
0.00 INR
5.00 INR
Jan 1, 2023
5.00 INR
0.00 INR
30.00 INR
Jan 1, 2024 (e)
35.00 INR
0.00 INR
5.00 INR
Jan 1, 2025
130.00 INR
0.00 INR
0.00 INR
Jan 1, 2026 (e)
130.00 INR
-88.54 INR
130.00 INR
Jan 1, 2027 (e)
0.00 INR
41.46 INR
0.00 INR
Jan 1, 2028 (e)
0.00 INR
49.12 INR
0.00 INR

Pfizer dividend payout ratio

In 2025, Pfizer had a payout ratio of 77.48%. The payout ratio indicates the percentage of the company's profits that Pfizer distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
4.60 %
Jan 1, 2022
48.55 %
Jan 1, 2023
3.67 %
Jan 1, 2024
29.04 %
Jan 1, 2025
77.48 %
Jan 1, 2026 (e)
24.62 %
Jan 1, 2027 (e)
22.37 %
Jan 1, 2028 (e)
24.08 %

Current Pfizer forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
2.20 %
Buy62.50 % (5)
Hold37.50 % (3)
Sell0.00 % (0)
12M Price Target
6,222.00
Last Price
4,731.40
Currency
INR
12M Return Potential
31.50 %
LTM Return
0 %

Pfizer Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/13/202433.33INR6.53 BINR2024 Q4
2/7/202440.20INR6.94 BINR2024 Q3

EESG©

Eulerpool ESG Scorecard© for the Pfizer stock

67/100
57
Environment
83
Social
61
Governance
E

Environment

20
Scope 1 - Direct Emissions56
Scope 2 - Indirect emissions from purchased energy1,619
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions1,676
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees15.457
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pfizer shareholder structure

% Name
63.92243%
Pfizer Inc
Pfizer Inc
4.17316%
Nippon Life India Asset Management Limited
Nippon Life India Asset Management Limited
3.85001%
Life Insurance Corporation of India
Life Insurance Corporation of India
2.22157%
Quant Money Managers Ltd
Quant Money Managers Ltd
2.12098%
ICICI Prudential Asset Management Co. Ltd.
ICICI Prudential Asset Management Co. Ltd.
2.09612%
Lalbhai Group
Lalbhai Group

Pfizer Executives and Management Board

MN

Mrs. Meenakshi Nevatia

(54)

Managing Director, Executive Director · since 2023

Compensation94.83 M INR
AA

Mr. Amit Agarwal

Chief Financial Officer, Executive Director - Finance · since 2024

Compensation34.58 M INR
PR

Mr. Pazhania Rengan

(46)

Executive Director - Plant Operations · since 2023

Compensation14.80 M INR
PS

Mr. Pradip Shah

(71)

Non-Executive Non-Independent Chairman of the Board · since 2024

Compensation2.46 M INR
MG

Ms. Meena Ganesh

Non-Executive Independent Director

Compensation2.39 M INR

Frequently asked questions about Pfizer

The business model of Pfizer Ltd revolves around pharmaceutical research, development, manufacturing, and sales. As a leading global biopharmaceutical company, Pfizer focuses on discovering breakthrough medicines and vaccines for various health conditions. With a diverse portfolio, Pfizer aims to improve patient lives and promote better health outcomes by investing in innovative research and development. Through strategic partnerships and collaborations, Pfizer strives to advance healthcare solutions while maintaining a strong commitment to delivering quality products. By upholding high standards of scientific integrity and ethical business practices, Pfizer continues to contribute to the well-being of individuals worldwide.

All fundamentals and in-depth analysis of Pfizer

Our stock analysis for Pfizer stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pfizer. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Pfizer Stock
Pfizer Revenue→
Pfizer Stock
Pfizer Net Income→
Pfizer Stock
Pfizer P/E→
Pfizer Stock
Pfizer P/S→
Pfizer Stock
Pfizer EBIT→
Pfizer Stock
Pfizer Dividend→
Pfizer Stock
Pfizer Directors Dealings→
Pfizer Stock
Pfizer Stocks→
Pfizer Stock
Pfizer Market capitalization→
Pfizer Stock
Pfizer Debt→
Pfizer Stock
Pfizer Liabilities→
Pfizer Stock
Pfizer Equity→
Pfizer Stock
Pfizer AAQS→
Pfizer Stock
Pfizer Employees→
Pfizer Stock
Pfizer ROE→
Pfizer Stock
Pfizer ROA→
Pfizer Stock
Pfizer ROCE→
Pfizer Stock
Pfizer News→
Pfizer Stock
Pfizer Analyst Price Targets→

Health Stocks

PhaarmasiaPfizerPhapros Tbk PTPetVivo HoldingsPharma Foods International CoPetros PharmaceuticalsPharma MarPet Pharm Biotech CoPharma-Bio ServPerspective TherapeuticsPharmaBlock Sciences NanjingPersonalisAll Stocks A–Z →